PDCD1 and neoplasm: To test the function of CM-MSNs as a cancer vaccine therapy in vivo, we inoculated Hepa1-6 cells into the right hind legs and then evaluated the combined effect of the nanomaterials and anti-PD1 on tumor growth (Figure 5A).